Anticancer thiopyrano[2,3-d][1,3]thiazol-2-ones with norbornane moiety. Synthesis, cytotoxicity, physico-chemical properties, and computational studies

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 15, 2006, Pages 5230-5240

  Lesyk, Roman ^a   Zimenkovsky, Borys ^a   Atamanyuk, Dmytro ^a,b   Jensen, Frank ^b   Kieć Kononowicz, Katarzyna ^c   Gzella, Andrzej ^d  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

3D QSAR; Anti cancer in vitro screening; Docking; RP TLC lipophilicity study; Thiopyrano 2,3 d thiazol 2 ones

Indexed keywords

9 (2' CHLOROPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (3',4' DIMETHOXYPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' BENZYLOXY 3' METHOXYPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' CHLOROPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' FLUOROPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' HYDROXY 3' METHOXYPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' HYDROXYPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' METHOXYPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (4' METHYLPHENYL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 (THIOPHEN 2 YL) 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; 9 [4 (2',5' DICHLOROPHENYL)FURAN 2 YL] 3,7 DITHIA 5 AZATETRACYCLO[9.2.1.0 2,10 .0 4,8 ]TETRADECEN 4(8) ONE; ANTINEOPLASTIC AGENT; NORBORNANE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CYTOTOXICITY; DIELS ALDER REACTION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; MODEL; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NORBORNANES; PYRANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

BETULACEAE;

EID: 33745167386     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.03.053     Document Type: Article

References (54)

1. Negwer, M. In Organic-Chemical Drugs and Their Synonyms (An International Survey)/By Martin Negwer, 7th ed.; Akademie: Berlin, 1994; Vols. 1-4.
2. Lesyk R.B., and Zimenkovsky B.S. Curr. Org. Chem. 8 (2004) 1547
3. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., and Yuan J. Nat. Cell Biol. 3 (2001) 173
4. Liu W., Bulgaru A., Haigentz M., Stein C.A., Perez-Soler R., and Mani S. Curr. Med. Chem.: Anti-Cancer Agents 3 (2003) 217
5. Lugovskoy A.A., Degterev A.I., Fahmy A.F., Zhou P., Gross J.D., Yuan J., and Wagner G. J. Am. Chem. Soc. 124 (2002) 1234
6. Carter P.H., Scherle P.A., Muckelbauer J.A., Voss M.E., Liu R.-Q., Thompson L.A., Tebben A.J., Solomon K.A., Lo Y.C., Li Z., Strzemienski P., Yang G., Falahatpisheh N., Xu M., Wu Z., Wu Z., Farrow N.A., Ramnarayan K., Wang J., Rideout D., Yalamoori V., Domaille P., Underwood D.J., Trzaskos J.M., Friedman S.M., Newton R.C., and Decicco C.P. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 11879
7. Chen H., Fan Y.-H., Natarajan A., Guo Y., Iyasere J., Harbinski F., Luus L., Christ W., Aktas H., and Halperin J.A. Bioorg. Med. Chem. Lett. 14 (2004) 5401
8. Theocharis S., Margeli A., and Kouraklis G. Curr. Med. Chem.: Anti-Cancer Agents 3 (2003) 239
9. Debril M.-B., Renaud J.-P., Fajas L., and Auwerx J. J. Mol. Med. 79 (2001) 30
10. Gelman L., Fruchart J.-C., and Auwerx J. Cell. Mol. Life Sci. 55 (1999) 932
11. Farrow B., and Evers B.M. Biochem. Biophys. Res. Commun. 301 (2003) 50
12. http://dtp.nci.nih.gov.
13. Komaritsa I.D., Baranov S.N., and Grishchuk A.P. Khimiya Geterotsiklicheskikh Soedinenii 4 (1967) 664
14. Chem. Abstr. 68 (1968) 49495
15. Grishchuk, A. P.; Komaritsa, I. D.; Baranov, C. N. U.S.S.R. Patent SU 197594, 1967 (in Russian).
16. Chem. Abstr. 68 (1968) 36112
17. Kassab N.A.L., Elnagdy M.H., Messeha N.A., and Ead H.A.R. J. Pract. Chem. 314 (1972) 799
18. Kassab N.A.L., Abd-Allah S.O., and Messeha N.A. J. Prakt. Chem./Chem-Ztg 316 (1974) 209
19. Kassab N.A.L., and Messeha N.A. J. Pract. Chem. 315 (1973) 1017
20. Kassab N.A.L., Abd-Allah S.O., and Abd-El-Razik F.M. Indian J. Chem., Sect. B 14 (1976) 864
21. Ead H.A.R., Kassab N.A.L., Koeppel H., Bloedorn W.-D., and Schleinitz K.-D. J. Prakt. Chem./Chem-Ztg 322 (1980) 155
22. Ead H.A.R., and Metwalli N.H. Egypt. J. Chem. 32 (1991) 691
23. Omar M.T., El-Aasar N.K., and Saied K.F. J. Chem. Res. (M) 11 (2001) 1127
24. Abd-Allah S.O., Hamouda H.A., and Ali F.A. Pharmazie 41 (1986) 101
25. Cremer D., and Pople J.A. J. Am. Chem. Soc. 97 (1975) 1354
26. Wilson A.J.C. International Tables for Crystallography Vol. C (1992), Kluwer Academic, Dordrecht
27. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., and Vaigro-Wolff A. J. Natl. Cancer Inst. 83 (1991) 757
28. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91
29. Boyd M.R. In: Teicher B.A. (Ed). Cancer Drug Discovery and Development Vol. 2 (1997), Humana Press 23-43
30. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., and Boyd M.R. J. Natl. Cancer Inst. 81 (1989) 1088
31. Paull K.D., Lin C.M., Malspeis L., and Hamel E. Cancer Res. 52 (1992) 3892
32. http://dtp.nci.nih.gov/docs/compare/compare.html.
33. Zaharevitz D.W., Holbeck S.L., Bowerman C., and Svetlik P.A. J. Mol. Graphics Modell. 20 (2002) 297
34. Pliska V., Testa B., and Van de Waterbeemd H. In: Pliska V., Testa B., and Van de Waterbeemd H. (Eds). Lipophilicity in Drug Action and Toxicology (1996), VCH, Weinheim 1-6
35. Van de Waterbeemd H., Smith D.A., Beaumont K., and Walker D.K. J. Med. Chem. 44 (2001) 1313
36. Mannhold R., Dross K., and Sonntag Ch. In: Pliska V., Testa B., and Van de Waterbeemd H. (Eds). Lipophilicity in Drug Action and Toxicology (1996), VCH, Weinheim 141-156
37. Dross K., Rekker R.F., de Vries G., and Mannhold R. Quant. Struct.-Act. Relat. 18 (1999) 549
38. Lipinski C.A., Lombardo L., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 46 (2001) 3
39. ®, Macromodel, Glide, Schrodinger L.L.C.
40. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Perry F., and Penkin P.S. J. Med. Chem. 47 (2004) 1739
41. ®, Fred, OpenEye Scientific Software, 3600 Cerrillos Rd., Suite 1107, Santa Fe, NM 87507, USA.
42. Chirlian L.E., and Francl M.M. J. Comput. Chem. 8 (1987) 894
43. ®03, Gaussian, Inc., Carnegie Office Park, Building Six, Carnegie, PA 15106, USA.
44. ® 6.0, CambridgeSoft Inc., 100 CambridgePark Drive, Cambridge, MA 02140, USA.
45. ®, ChemAxon, ChemAxon Ltd, Máramaros köz 3/a, Budapest 1037, Hungary.
46. Willet P. J. Chem. Inf. Comput. Sci. 38 (1998) 983
47. Rannar S., Lindgren F., Geladi P., and Wold S. J. Chemom. 8 (1994) 111
48. http://dasher.wustl.edu/..
49. Turkevych N.M., Vvedenskij V.M., and Petlichnaya L.P. Ukr. Khim. Zh. (Russ. Ed.) 27 (1961) 680
50. Chem. Abstr. 56 (1962) 73455
51. Kuma Diffraction 1996. Version 8.0.1. KM-4 Software User's Guide, Wrocław, Poland.
52. Sheldrick, G. M. SHELXS-97 and SHELXL-97. Release 97-2. University Göttingen, Germany, 1997.
53. Farrugia L.J. J. Appl. Crystallogr. 30 (1997) 565
54. Farrugia L.J. J. Appl. Crystallogr. 32 (1999) 837